Edit Entry

Alan I. Green, MD

Title(s):
Chair and Professor of Psychiatry
Professor of Molecular and Systems Biology

Additional Titles/Positions/Affiliations:
Chairman, Department of Psychiatry
Director, SYNERGY: Dartmouth Clinical and Translational Science Institute
Associate Dean for Clinical and Translational Science, Geisel School of Medicine at Dartmouth
Raymond Sobel Professor of Psychiatry, Geisel School of Medicine at Dartmouth

Department(s):
Psychiatry
Molecular and Systems Biology

Education:
Columbia College, A.B. 1965
The Johns Hopkins University School of Medicine, M.D. 1969

Programs:
Neuroscience Center at Dartmouth
Program in Experimental and Molecular Medicine
Psychopharmacology Research Group
SYNERGY

Websites:
Geisel School of Medicine at Dartmouth, Department of Psychiatry
http://geiselmed.dartmouth.edu/psych/

SYNERGY (Dartmouth Center for Clinical and Translational Science)
http://synergy.dartmouth.edu

Neuroscience Center at Dartmouth
http://geiselmed.dartmouth.edu/ncd/

PEMM at Dartmouth
http://geiselmed.dartmouth.edu/pemm/

Contact Information:

Department of Psychiatry
Geisel School of Medicine at Dartmouth
DHMC 1 Medical Center Drive
Lebanon NH 03756

Office: Same
Phone: 603-650-7549
Fax: 603-650-8415
Email: alan.i.green@dartmouth.edu

Assistant: Danillie L. Mars
Asst. Phone: 603-650-7549
Asst. Email: Danillie.L.Mars@hitchcock.org


Professional Interests:

Schizophrenia and comorbid substance use disorder: neuropharmacology, neuroimaging and treatment development
Medication development for addiction
Brain reward circuitry
Animal models
Early intervention in schizophrenia

Dr. Green's research program, which involves clinical and neurobiological studies of patients with schizophrenia, particularly those with co-occurring substance use disorders, medication development studies for patients with alcoholism, and studies of alcohol drinking animals, has been funded by a series of grants from NIH, NARSAD and industry. He and his colleagues have proposed a neurobiological model suggesting that co-occurring substance use disorder in patients with schizophrenia relates, at least in part, to deficiencies in dopamine-mediated brain reward circuits. Data from his group have suggested that the novel antipsychotic medication clozapine limits alcohol and other substance use in these patients; he has proposed that the unique effects of clozapine in these patients relates to the mechanism of action of the drug, including its effects in brain reward circuits. On-going studies are continuing to probe the optimal psychopharmacological strategies for patients with co-occurring disorders through clinical trials, neuroimaging studies in humans, and a series of pharmacologic, neuroimaging and neurostimulation investigations in animals.

Rotations and Thesis Projects:

1) Medication development for alcohol drinking in rodents.
2) Neuroimaging and brain reward circuitry in schizophrenia.

Grant Information:

R21DA044501 (Green) 09/01/2017 – 08/31/2019
NIDA
Reward circuit dysfunction, substance use disorder, and schizophrenia: a preclinical fMRI-based connectivity study
The goal of this proposal is to begin to bridge the gap between clinical studies and our theoretical formulation of the basis of substance use in schizophrenia through study of fMRI connectivity in the NVHL rat.

R01DA034699 ( Green) 09/01/2013 – 03/31/2020
NIDA
Cannabis, schizophrenia and reward: self-medication and agonist treatment?
Using neuroimaging techniques, as well as behavioral measures of reward responsiveness, this study aims to assess the effects of smoked cannabis and oral dronabinol (THC) on the brain reward circuit in patients with schizophrenia and co-occurring cannabis use disorder, as well as in patients with cannabis use disorder alone.

1 UL1 TR001086-01; 1KL2TR001088-01 (Green) 09/26/2013 – 04/30/2019
NCATS
SYNERGY| The Dartmouth Clinical and Translational Science Institute
SYNERGY| The Dartmouth Clinical and Translational Science Institute (CTSA) seeks to promote and substantially strengthen Dartmouth's basic, clinical, translational and outcomes research potential.

3UL1TR001102-04S1 (Nadler) 06/01/2016 – 04/30/2018
NCATS
Harvard Clinical and Translational Science Center (Supplement): SMART IRB
This study aims to provide flexible resources that investigators nationwide can use to harmonize and streamline IRB review for their own multisite studies.
Role: Co-Investigator

1UH2DA041713 (Marsch/Poldrack) 09/15/2015 – 08/31/2020
NIH/NIDA (via NIH Common Fund)
Applying Novel Technologies and Methods to Inform the Ontology of Self-Regulation
This study will examine putative targets (processes) of behavior change within the self-regulation mechanism domain across contexts, populations, and assays – in 3 primary levels of analysis: (1) psychological (e.g., constructs such as self-efficacy; emotion regulation; response inhibition), (2) behavioral (e.g., tasks of reward responsiveness; temporal horizon), and (3) biological (structural and functional MRI of key neural circuitry).
Role: Co-investigator

Courses Taught:

Psychopharmacology
Graduate and Medical Pharmacology
Neuroscience of Psychiatric Disorders

Biography:

Alan I. Green, M.D. is the Raymond Sobel Professor of Psychiatry, Professor of Molecular and Systems Biology, and Chairman of the Department of Psychiatry at Geisel School of Medicine at Dartmouth.
Director, Dartmouth SYNERGY, The Dartmouth Clinical and Translational Science Institute.

He received his B.A. from Columbia College and his M.D. degree from the Johns Hopkins University School of Medicine. Following an internship in medicine at the Beth Israel Hospital in Boston, he was a research associate at the National Institute of Mental Health and was Director of Biomedical Research at the Special Action Office for Drug Abuse Prevention in the Executive Office of the President. He did his psychiatry residency and a clinical research fellowship at the Harvard-based Massachusetts Mental Health Center. He joined the Harvard faculty in 1984 and was Director of the Commonwealth Research Center at Harvard Medical School from 1987 until 2002. He joined the Geisel School of Medicine's Department of Psychiatry as Professor and Chairman in November 2002, and he became Director of Dartmouth SYNERGY in 2012. He has been a highly productive and active investigator, has received peer-reviewed funding throughout his career, has mentored over 45 trainees, and is the author of more than 300 papers and abstracts.

Mentoring Information:

Dr. Green has been the primary research mentor for over 45 predoctoral and postdoctoral trainees. At present, he is the primary mentor for a number of junior investigators, post-doctoral research fellows, graduate students, and undergraduates.


Selected Publications:

 

  • Brown ES, Green A. A Focus on Topics Related to Smoking and PTSD. Journal of Dual Diagnosis, 2018. 1-2. (view details on MedLine)

  • Eisenberg IW, Bissett PG, Canning JD, Dallery J, Enkavi AZ, Gabrieli SW, Gonzalez O, Green AI, Greene MA, Kiernan M, Kim SJ, Li J, Lowe M, Mazza GL, Metcalf SA, Onken L, Parikh SS, Peters E, Prochaska JJ, Scherer EA, Stoeckel LE, Valente MJ, et al. Applying novel technologies and methods to inform the ontology of self-regulation. Behavioral Research and Therapy, 2018. 101:46-57. PMCID: PMC5801197 (view details on MedLine)

  • Khokhar J, Green AI. Unique Effects of Clozapine: A Pharmacological Perspective. Advances in Pharmacology, 2018. 82: 137-162. (view details on MedLine)

  • Green AI, Khokhar J. Addiction and schizophrenia: a translational perspective. Schizophrenia Research, 2018. 194: 1-3. (view details on MedLine)

  • Whitfield-Gabrieli S, Fischer AS, Roth RM, Brunette MF, Green AI. Understanding marijuana’s effects on functional connectivity of the default mode network in patients with schizophrenia and co-occurring cannabis use disorder: a pilot investigation. Schizophrenia Research, 2018. 194:70-77. (view details on MedLine)

  • Khokhar J, Dwiel LL, Henricks AM, Doucette WT, Green AI. The link between schizophrenia and substance use disorder: a unifying hypothesis. Schizophrenia Research, 2018. 194: 78-85. (view details on MedLine)

  • Brunette MF, Akerman SC, Dawson R, O’Keefe CD, Green AI. An open-label pilot study of quetiapine plus mirtazapine for heavy drinkers with alcohol use disorder. Alcohol, 2016. 53:45-50. (view details on MedLine)

  • Khokhar J, Green AI. Effects of iloperidone, combined with desipramine, on alcohol drinking in the Syrian golden hamster. Neuropharmacology, 2016. 105:25-34. PMC4873404 (view details on MedLine)

  • Doucette WT, Khokhar JY, Green AI. Nucleus accumbens deep brain stimulation in a rat model of binge eating. Translational Psychiatry, 2015. 5:e695. PMC5068592 (view details on MedLine)

  • Green AI, Brunette MF, Dawson R, Buckley P, Hafez H, Herz M, Narasimhan M, Noordsy D, O’Keefe C, Sommi RW, Weeks M. Long-acting Injectable vs. Oral Risperidone for Schizophrenia and Co-occurring Alcohol Disorder: A Randomized Trial. The Journal of Clinical Psychiatry, 2015. 76(10):1359-1365. (view details on MedLine)